In conclusion, this study evaluated the cardiac safety of lazertinib 20 mg to 320 mg in Korean patients with EGFRm locally advanced or metastatic NSCLC who had previously received EGFR TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.